Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT02702323
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
  • TACE — PROCEDURE
    one times every 4-6 weeks.

Study Details

This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization (TACE) therapy in combination,while the other half will receive TACE therapy alone.

Key Dates

Start date
Mar 31, 2016
Status verified
Mar 2016
Primary completion
Mar 31, 2018
Completion
Mar 31, 2019

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib & TACE
    Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
  • Active Comparator: TACE
    TACE therapy one times every 4-6 weeks.

Primary Outcome Measure

Progress Free Survival [ Time Frame: Change from Baseline mRECIST at 12 months was assessed every 4 weeks up to 48 weeks. Data collection is from date of randomization until the date of first documented progression assessed up to 12 months. ]

Central Contacts

Related Studies